InvestorsHub Logo
Followers 176
Posts 15161
Boards Moderated 2
Alias Born 01/30/2014

Re: TAKURI post# 39064

Tuesday, 06/07/2022 12:47:23 PM

Tuesday, June 07, 2022 12:47:23 PM

Post# of 39185
This year 2021, the Company has entered into an agreement with CVS Pharmacy to participate in their Test & Learn Program for our flagship product, Emesyl®. We initially received two purchase orders from CVS which involvedshippingEmesyl®productstotwoCVSdistributioncentersinTexas. Fromthere,weexpecttheprogram to place Emesyl® in 100 retail stores across the country, entering into a 24-week analysis phase. We expect to gather weekly feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seems to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an action plan will be developed by the CVS category manager to expand distribution to 8000+ stores, which is typically executed in their next CVS planogram cycle. At this moment, we will see what the Test & Learn Program will tell us.

https://www.otcmarkets.com/otcapi/company/financial-report/326034/content